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A new roadmap for childhood tuberculosis 
On Oct 1, 2013, WHO and global partners launched 
a roadmap to end tuberculosis deaths in children 
worldwide.1 The roadmap identiﬁ es key actions that 
must be taken, including increased and targeted 
research, partnerships between key stakeholders, 
and strategic economic investment. The roadmap 
also shows the crucial lack of global emphasis on 
tuberculosis prevention and treatment for one of 
the most vulnerable populations. This intervention 
comes at a pivotal juncture because rates of drug-
resistant tuberculosis have been increasing worldwide, 
particularly in the WHO European Region, with severe 
implications for child tuberculosis morbidity and 
mortality.
Globally, children younger than 15 years account for 
about 6% of the 8·6 million cases of tuberculosis, and 
about 5% of the 1·4 million deaths that occur annually 
from the disease.2,3 Children have been traditionally 
viewed to pose less of a risk for transmission than 
adults because they often have paucibacillary disease, 
which is also harder to diagnose with sputum smear 
microscopy, culture, and molecular tests.4 If tuberculosis 
is undetected and untreated, children are at high 
risk of death, especially in the context of multidrug-
resistant and extensively drug-resistant tuberculosis. 
15 of the 27 countries with a high burden of multidrug-
resistant and extensively drug-resistant tuberculosis 
worldwide are in the WHO European Region,2 with 
99% of the regional disease burden in 18 high-priority 
countries (Armenia, Azerbaijan, Belarus, Bulgaria, 
Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, 
Lithuania, Moldova, Romania, Russia, Tajikistan, Turkey, 
Turkmenistan, Ukraine, and Uzbekistan).5 6% of the total 
estimated incidence of new and relapsed tuberculosis 
cases occurred in these countries (376 200 cases),2,5 in 
2011, an estimated 23 000 children had tuberculosis, 
of whom nearly 5000 are estimated to have had 
multidrug-resistant or extensively drug-resistant 
disease. These estimates contrast sharply with the fewer 
than 1000 cases of childhood tuberculosis that were 
detected and reported in these countries.2,5
In response to the alarming increase in multidrug-
resistant and extensively drug-resistant tuberculosis in 
the WHO European Region, in 2011 the Consolidated 
Action Plan to Prevent and Combat Multidrug and 
Extensively Drug Resistant Tuberculosis (2011–15) was 
endorsed by the sixty-ﬁ rst Regional Committee for 
Europe, and implemented in all 53 member states.6,7 
The plan includes essential milestones and activities 
for childhood tuberculosis, with the aim to scale-up 
access to treatment; prioritise childhood tuberculosis in 
member states’ national strategic plans; and develop 
a special response for diagnosis and treatment of 
tuberculosis in children, including identifying policies 
(or lack of policies) that contribute to underdiagnosis. 
The table summarises data on national childhood 
tuberculosis policies collected by the WHO Europe 
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 Number of 
high-priority 
countries (n=15)*
Case detection  
Contact tracing†  
Close household 15
Close non-household 8
Casual 7
Community 6
Examinations if tuberculosis contact†  
TST 15
Bacteriological examination 9
Interferon-γ-release assays 3
Radiograph of the chest 14
Fluorography 3
CT 9
Other blood analyses 10
Preventive treatment  
Preventive treatment for latent tuberculosis†  
Children with tuberculosis contact, irrespective of age and irrespective of TST results 7
Children with tuberculosis contact, irrespective of age with a positive TST 8
Children with tuberculosis contact, with positive TST of certain age range 2
Children detected through mass tuberculin skin testing with a positive TST, 
irrespective of age
2
Children with HIV 8
Other 7
Type of preventive treatment†  
Isoniazid 15
Other 4
Preventive treatment for child contacts of MDR tuberculosis patients (individualised 
treatment on the basis of drug-resistance pattern of index case)
 4
Preventive admission to hospital  
Yes, for the entire treatment period 3
Yes, for the initial period 3
No, treatment is given ambulatory for the full period 6
Ambulatory for the full period with a proportion of children referred to sanatoriums 3
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task force for childhood tuberculosis from 15 (of 
the 18) high-priority countries that provided policy 
information from September, 2012, to January, 2013.3 
At present, the 15 countries have policies that adhere to 
the 2006 WHO guidelines for childhood tuberculosis4 
with regard to contact-tracing of close household 
contacts, detection with tuberculin skin testing, 
and provision of isoniazid preventive treatment for 
children with a close household tuberculosis contact. 
However, only eight countries have policies for contact 
tracing for children with a close non-household contact 
(as recommended by WHO for children younger than 
5 years8). Additionally, four countries recommend a 
multidrug-resistant tuberculosis treatment regimen 
only in children with bacteriologically conﬁ rmed 
multidrug-resistant tuberculosis. However, since 
bacteriological conﬁ rmation is often diﬃ  cult in 
children, WHO recommends that, if active tuberculosis 
disease develops in children with a close contact with 
multidrug-resistant tuberculosis, a multidrug-resistant 
tuberculosis drug regimen should be promptly started. 
Although 11 countries have this policy in place, its 
eﬃ  cacy is predicated on eﬀ ective contact investigation. 
For children who are detected with active tuberculosis 
or are given preventive therapy for latent infection, 
several countries require hospital admission for either 
the initial 2 month phase or the entire length of 
preventive and active tuberculosis treatment (three 
and seven countries, respectively). However, admission 
of children to tuberculosis wards for an unnecessarily 
long duration places them at high risk of primary 
infection or reinfection with multidrug-resistant or 
extensively drug-resistant tuberculosis.9,10 Forthcoming 
updated WHO guidelines for the management of 
childhood tuberculosis will add clarity for countries 
about these and other issues, including detection 
with molecular diagnostics and use of paediatric drug 
formulations. 
In the context of multidrug-resistant and extensively 
drug-resistant tuberculosis, a priority in the WHO 
European region is to accelerate the adoption of 
updated childhood tuberculosis guidelines into national 
strategic tuberculosis policies. Additionally, eﬀ orts to 
ensure that policy is aligned with practice remain at the 
core of eﬀ ectively detecting disease and saving lives of 
children with tuberculosis. In high-priority countries, 
there is a crucial scarcity of qualiﬁ ed human resources 
to manage childhood tuberculosis and multidrug-
resistant and extensively drug-resistant tuberculosis, 
and irregular access to second-line drugs is still a 
challenge. The new roadmap for childhood tuberculosis 
importantly serves as a call to action for all stakeholders 
in child health to urgently address these issues.
Key actions to increase awareness and capacity for 
contact investigation, management of childhood 
tuberculosis, and surveillance are in line with the 
Consolidated Action Plan. These actions will be vital 
to shift policy and place a spotlight on prevention and 
combat of multidrug-resistant and extensively drug-
resistant tuberculosis in the most vulnerable populations.4
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 Number of 
high-priority 
countries (n=15)*
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Treatment for active tuberculosis disease  
Paediatric national guidelines 14
Standardised treatment for active or assumed drug-sensitive tuberculosis 15
Children prescribed MDR regimen  
Only children with bacteriologically conﬁ rmed MDR tuberculosis 4
Both children with bacteriologically conﬁ rmed MDR tuberculosis and children with 
active tuberculosis in close contact with patients with infectious MDR tuberculosis
11
Type of MDR treatment  
Individualised 9
Standardised 3
Both 2
Admission to hospital for active tuberculosis†  
Yes, for the entire treatment period 7
Yes, for the initial period 3
No, ambulatory for the full period 5
Ambulatory treatment preferred, but hospital stay might be necessary 5
TST=tuberculin skin test. MDR=multidrug-resistant.*Armenia, Belarus, Estonia, Georgia, Kazakhstan, Kyrgyzstan, 
Latvia, Lithuania, Moldova, Russia, Tajikistan, Turkey, Turkmenistan, Ukraine, and Uzbekistan. †Categories not 
mutually exclusive. 
Table: Number of countries with policies for detection, preventive treatment, and active treatment of 
children with tuberculosis
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